Management Change/Compensation - Form 8-K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 10, 2024, Talis Biomedical Corporation (the "Company") entered into a retention agreement (the "Retention Agreement") with Rebecca Markovich, Interim Chief Financial Officer. Under the terms of the Retention Agreement, Ms. Markovich is eligible to receive $89,250 if she maintains satisfactory job performance and remains employed with the Company through the completion of a sale, merger or liquidation and dissolution of the Company. The Company intends to file a copy of the Retention Agreement as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024.